Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Istvan Kenessey
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
Cancers
Cancer Research
Oncology
High VEGFR-3-positive Circulating Lymphatic/Vascular Endothelial Progenitor Cell Level Is Associated With Poor Prognosis in Human Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer
JAMA Oncology
Cancer Research
Oncology
FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer
World Journal of Surgical Oncology
Surgery
Oncology
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Is an Independent Prognostic Marker in Wild-Type KRAS Metastatic Colorectal Cancer After Colorectal Liver Metastasectomy
BMC Cancer
Cancer Research
Oncology
Genetics
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Clinical Colorectal Cancer
Oncology
Gastroenterology
PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Co-Expression and Prognostic Significance of Putative CSC Markers CD44, CD133, Wild-Type EGFR and EGFRvIII in Metastatic Colorectal Cancer
Oncotarget
Oncology
A Small Molecule Approach to Degrade RAS With EGFR Repression Is a Potential Therapy for KRAS Mutation-Driven Colorectal Cancer Resistance to Cetuximab
Experimental and Molecular Medicine
Biochemistry
Medicine
Clinical Biochemistry
Molecular Biology
Molecular Medicine
PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients
British Journal of Cancer
Cancer Research
Oncology
